Recursion Pharmaceuticals... (RXRX)

Recursion Pharmaceuticals (RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names. Rec...

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 1.49%) is slimming down and streamlining. After the biotech updated its strategy to do so on Tu...

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech industr...

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Most investors are best served by owning high-quality "forever" stocks, even if these stocks are only apt to produce average returns.

Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.

Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention.

The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automat...

Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday.